Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Nov 15;18(22):6086-8.
doi: 10.1158/1078-0432.CCR-12-2801. Epub 2012 Oct 10.

Regulatory T cells move in when gliomas say "I Do"

Bryan D Choi  1 , Peter E Fecci, John H Sampson
Affiliations
Comment

Regulatory T cells move in when gliomas say "I Do"

Bryan D Choi et al. Clin Cancer Res. .

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression. IDO inhibition may therefore provide a promising therapeutic approach for glioblastoma, where the need for novel treatment is great.

PubMed Disclaimer

Conflict of interest statement

The authors do not report conflicts of interest.

Figures

Figure 1
Figure 1
Tregs accumulate in brain tumors and are associated with poor prognosis. Peripheral depletion with anti-CD25 antibodies and CTLA-4 blockade are methods by which antitumor immune responses may be enhanced. IDO-mediated catabolism of tryptophan occurs in both tumor cells and peripherally in DCs. Here, IDO enzymatic activity potentiates an immune tolerogenic environment resulting in the reciprocal induction of Tregs amidst a suppressed effector T-cell response.
See this image and copyright information in PMC

Comment on

References

    1. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 - PMC - PubMed
    1. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008;222:70–100. - PMC - PubMed
    1. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294–302. - PubMed
    1. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8:234–43. - PMC - PubMed
    1. Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol. 2009;39:1323–33. - PubMed

Publication types

MeSH terms

Substances